IMDELLTRA Plus IMFINZI Reduces Death Risk by 58% in Extensive Stage Small Cell Lung Cancer

Interim Phase 3 results from the DeLLphi-305 study, presented at the ESMO Congress 2026 and simultaneously published in The New England Journal of Medicine, demonstrated that IMDELLTRA (tarlatamab-dlle) in combination with IMFINZI (durvalumab) reduced the risk of death by an unprecedented 58% as a first-line maintenance treatment for extensive stage small cell lung cancer (ES-SCLC). The combination extended median overall survival by over eight months, offering a significant advance for this aggressive disease.